Separately, ValuEngine downgraded Pulse Biosciences from a buy rating to a hold rating in a report on Tuesday, September 10th.
PLSE opened at $15.63 on Friday. The business’s 50-day moving average is $12.98 and its two-hundred day moving average is $13.77. Pulse Biosciences has a 1 year low of $8.60 and a 1 year high of $19.77. The company has a debt-to-equity ratio of 0.07, a current ratio of 12.92 and a quick ratio of 12.92. The firm has a market capitalization of $324.64 million, a PE ratio of -7.10 and a beta of 1.84.
Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, sell-side analysts expect that Pulse Biosciences will post -2.29 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its position in Pulse Biosciences by 1,082.7% during the first quarter. BNP Paribas Arbitrage SA now owns 2,259 shares of the company’s stock valued at $40,000 after acquiring an additional 2,068 shares in the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Pulse Biosciences in the second quarter valued at approximately $5,074,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Pulse Biosciences in the second quarter valued at approximately $55,000. Bank of Montreal Can increased its position in shares of Pulse Biosciences by 15.0% in the second quarter. Bank of Montreal Can now owns 8,053 shares of the company’s stock valued at $106,000 after buying an additional 1,053 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Pulse Biosciences by 7.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,993 shares of the company’s stock valued at $357,000 after buying an additional 1,853 shares in the last quarter. 9.87% of the stock is owned by hedge funds and other institutional investors.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.